• Disease Overview
  • Synonyms
  • Signs & Symptoms
  • Causes
  • Affected Populations
  • Disorders with Similar Symptoms
  • Diagnosis
  • Standard Therapies
  • Clinical Trials and Studies
  • References
  • Programs & Resources
  • Complete Report

Goodpasture Syndrome


Last updated: September 17, 2007
Years published: 1986, 1987, 1988, 1989, 1997, 2002, 2003, 2007

Disease Overview

Goodpasture syndrome is a rare autoimmune disorder characterized by inflammation of the filtering structures (glomeruli) of the kidneys (glomerulonephritis) and excessive bleeding into the lungs (pulmonary hemorrhaging). Autoimmune syndromes occur when the body’s natural defenses (antibodies) against invading or “foreign” organisms begin to attack the body’s own tissue, often for unknown reasons. Symptoms of Goodpasture syndrome include recurrent episodes of coughing up of blood (hemoptysis), difficulty breathing (dyspnea), fatigue, chest pain, and/or abnormally low levels of circulating red blood cells (anemia). In many cases, Goodpasture syndrome may result in an inability of the kidneys to process waste products from the blood and excrete them in the urine (acute renal failure). In some cases of Goodpasture syndrome, affected individuals have had an upper respiratory tract infection before the development of the disorder. The exact cause of Goodpasture syndrome is not known.

  • Next section >
  • < Previous section
  • Next section >


  • Pneumorenal Syndrome
  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Signs & Symptoms

The major symptoms of Goodpasture syndrome are excessive bleeding into the lungs (pulmonary hemorrhaging) and inflammation of the filtering structures (glomeruli) or the kidneys (glomerulonephritis). In some cases, an upper respiratory tract infection may precede the development of the disorder. General symptoms associated with Goodpasture syndrome may include fever, nausea, and fatigue.

Pulmonary hemorrhaging may lead to episodes where affected individuals cough up blood (hemoptysis). The severity of this finding may range from a few flecks to excessive amounts of blood. Affected individuals may also exhibit difficult breathing (dyspnea), fatigue, chest pain, a dry rasping sound from the throat (rhoncus), and/or frequent coughing. In rare cases, affected individuals may exhibit abnormal accumulation of fluid (edema) in the tissue of the lungs. Pulmonary abnormalities are usually noted before or simultaneous to kidney (renal) abnormalities in approximately 70 percent of the cases.

Inflammation of the filtering structures (glomeruli) of the kidneys (glomerulonephritis) may lead to an inability of the kidneys to process waste products from the blood and excrete them in the urine (acute renal failure). Renal failure usually leads to a decrease in the amount of urine the body produces. Additional symptoms associated with renal failure may include abnormally pale skin (pallor), drowsiness, nausea, and/or vomiting. Severe complications of renal failure include bleeding into the stomach and/or a decrease in the amount of circulating red blood cells (anemia).

In rare cases, affected individuals may exhibit high blood pressure (hypertension) and/or pain and swelling of the joints (arthritis). In some cases, symptoms of Goodpasture syndrome may recur after treatment.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >


Goodpasture syndrome develops due to unknown causes. Environmental factors such as hydrocarbon chemical exposure, cigarette smoke, or infections such as influenza may play a role in the development of the disorder. It is not known why simple infections can progress to Goodpasture syndrome in some people. When infection occurs, the body’s natural defenses (antibodies) fight the invading organisms (e.g., viruses or bacteria). In autoimmune disorders, antibodies attack healthy tissue for no apparent reason. Pulmonary hemorrhage has been frequently associated with smoking in individuals with Goodpasture syndrome.

In Goodpasture syndrome, certain antibodies (anti-glomerular basement membrane [anti-GBM] antibodies) may be produced and circulate throughout the blood. These antibodies may damage the delicate membranes that line the lungs and kidneys or the tiny blood vessels (capillaries) within the lungs and kidneys.

In some cases, individuals with Goodpasture syndrome may have an association with human leukocyte antigens (HLAs). HLAs are proteins that play an important role in the body’s immune system; they influence the outcome of transplantation and appear to affect an individual’s predisposition to certain diseases. However, the implications of such findings are not fully understood.

Goodpasture syndrome has been reported in more than one family member (e.g., siblings) in a few cases, supporting the possibility of genetic susceptibility as a factor in some cases. A person who is genetically predisposed to a disorder carries a gene (or genes) for the disease, but it may not be expressed unless it is triggered or “activated” under certain circumstances, such as due to particular environmental factors (multifactorial inheritance).

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Affected populations

Goodpasture syndrome is a rare autoimmune disorder that appears to affect males more frequently than females. Age of onset is usually between 20 and 30, but individuals at any age may be affected.

Goodpasture syndrome was first identified in 1919. Since that time approximately 600 cases have been noted in the medical literature.

In the US the Anti-GBM disease is an uncommon disorder; approximately 1-2% of all cases of rapidly progressive glomerulonephritis are secondary to this disorder.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >


A diagnosis of Goodpasture syndrome may be suspected based upon the identification of characteristic physical findings (e.g., pulmonary hemorrhaging and glomerulonephritis). The diagnosis may be confirmed by the identification of the presence of anti-glomerular basement membranes antibodies in the body. In some cases, affected individuals may exhibit blood (hematuria) and/or protein (proteinuria) in the urine.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Standard Therapies


Mild forms of Goodpasture syndrome may be treated with the use of drugs that suppress or hinder the effectiveness of the body's immune system (immunosuppressive drugs). Corticosteroids such as prednisone may be administered to control bleeding in the lungs (pulmonary hemorrhaging).

Many affected individuals may be treated with plasmapheresis. This procedure is a method for removing unwanted substances (toxins, damaging antibodies, and metabolic substances) from the blood. Blood is removed from the patient and blood cells are separated from plasma. The patient's plasma is then replaced with other human plasma and the blood is transfused into the patient. This therapy is still under investigation to analyze side effects and effectiveness. Plasmapheresis is often administered in conjunction with corticosteroid treatment.

In severe and repeated cases of Goodpasture syndrome affected individuals may be treated with a procedure where waste products are removed from the blood (dialysis). In the most severe cases, a kidney transplant may be needed.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Clinical Trials and Studies

Changes from nonspecific to more selective methods of plasmapheresis are under investigation in the treatment of Goodpasture syndrome as well as many other autoimmune disorders. These methods may include cascade filtration, cryofiltration, immunoabsorption, enzymatic degradation, and continuous electrophoresis. These procedures appear to be significant advances in clinical and experimental immunology therapeutic research. In immunoabsorption, only immunoglobulins (antibodies) are removed from an affected individual’s blood stream.

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:


  • < Previous section
  • Next section >
  • < Previous section
  • Next section >



Magalini SI, et al., eds. Dictionary of Medical Syndromes. 4th ed. New York, NY: Lippincott-Raven Publishers; 1997:330-31.

Stein JH, et al., eds. Internal Medicine, 4th Ed..: Mosby-Year Book, Inc.; 1994:2706.

Brenner BM, et al., eds. The Kidney, 4th ed. Philadelphia, PA: W. B. Saunders Company; 1991:1301-05.

Fishman AP, ed. Pulmonary Diseases and Disorders, 2nd ed. New York, NY: McGraw-Hill Book Company; 1988:675-81.


Shah MK, Hugghins SY, Characteristics and outcomes of patients with Goodpasture’s syndrome. South Med J. 2002;95:1411-8.

Shah MK. Outcomes in patients with Goodpature’s syndrome and hydrocarbon exposure. Ren Fail. 2002;24:545-55.

Lettiere C, Pina J. Goodpasture’s syndrome: a case of delayed appearance of autoantibodies and renal disease. Mil Med. 2001;166:827-30.

Levy JB, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134:1033-42.

Laczika K, et al. Immunoadsorption in Goodpasture’s syndrome. Am J Kidney Dis. 2000;36:392-95.

Von Vigier RO, et al. Pulmonary renal syndrome in childhood: a report of twenty-one cases and a review of the literature. Pediatr Pulmonol. 2000;29:382-88.

Phelps RG, Rees AJ. The HLA complex in Goodpasture’s syndrome: a model for analyzing susceptibility to autoimmunity. Kidney Int. 1999;56:1638-53.

Levy JB, et al. Recurrent Goodpasture’s disease. Am J Kidney Dis. 1996;27:573-78.

Turner AN, et al. Goodpasture’s disease and Alport’s syndromes. Annu Rev Med. 1996;47:377-86.

Kalluri R, et al. Specificity of circulating and tissue-bound autoantibodies in Goodpasture syndrome. Proc Assoc Am Physicians. 1996;108:134-39.

Molinier S, et al. Goodpasture syndrome: role of an epidemiological factor? Apropos of two cases. Rev Med Interne. 1995;16:589-94.

Izquierdo PM, et al. Goodpasture’s syndrome with negative renal immunofluorescence. Med Clin (Barc). 1996;106:784-86.

Moreso F, et al. Therapeutic immunoadsorption in Goodpasture disease. Med Clin (Barc). 1995;105:59-61.

Kelly PT, et al. Goodpasture syndrome: molecular and clinical advances. Medicine (Baltimore). 1994;73:171-85.

McCarthy LJ, et al. Goodpasture’s syndrome in childhood: treatment with plasmapheresis and immunosuppression. J Clin Apheresis. 1994;9:116-19.

Liebert A, et al. Immunomodulation with apheresis technics. Allerg Immunol (Leipz). 1986;32:5-18.

Marcandoro J, et al. Goodpasture’s syndrome: development of its prognosis from 1955 to 1982. Presse Med. 1985;12:1483-87.

Holdsworth S, et al. The clinical spectrum of acute glomerulonephritis and lung haemorrhage (Goodpasture’s syndrome). Q J Med. 1985;55:75-86.


McKusick VA, ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No: 233450; Last Update:6/13/95.

eMedicine – Goodpasture Syndrome : Article by Sat Sharma, MD


  • < Previous section
  • Next section >

Programs & Resources

RareCare® Assistance Programs

NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.

Additional Assistance Programs

MedicAlert Assistance Program

NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.

Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/

Rare Disease Educational Support Program

Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.

Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/

Rare Caregiver Respite Program

This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.

Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/

Patient Organizations

National Organization for Rare Disorders